In summary, despite having a higher tumor burden, higher level of AFP, larger proportion of patients with Child-Puge grade B, ECOG PS 2, PVTT, and extrahepatic metastasis, the studies confirmed superior PFS, OS, or ORR compared with Phase Ib Study and the IMbrave150 trial (31, 49, 50). The gene discussed is AFP; the disease is neoplasm.